Showing posts with label Drug Manufacturer. Show all posts
Showing posts with label Drug Manufacturer. Show all posts

Tuesday, March 5, 2013

Big Pharma Companies, Good and Bad

Big Pharma is both good and evil. Regardless of its motives, Big Pharma has prolonged our lives or kept our lifespan about this same (which is remarkable considering how fat an unhealthy we are). Maybe we all need a wake-up call to realize that a longer life isn't necessarily a better life... I for one would rather die at 70 then to live from 75 - 95 in a nursing home staring at a TV drooling while some nurse changes my poop filled depends twice a day.

If you want to give Big Pharma the proverbial 'middle finger' then put down the fork, the cigs, and get off of your couch and do 30 - 60 minutes of exercising a day (the anti-glutton effect). This will lower your blood pressure (no more ACEs, ARBs, beta blockers, CCBs, alpha antagonists), cholesterol (bye bye statins, niacin, fibrates and zetia), reverse diabetes (no more metformin, TZDs, insuline), and prevent heart attack (adios plavix/effient/brillinta).

Yes, I realize that genetics and other uncontrollable factors cause illness... but many things are preventable by not smoking, eating decent, and exercising. But if you choose to ignore the anti glutton effect fact, then don't you dare b*tch about "Big Pharma" and "Big Medicine."

Generic drugs help defray the cost pharma drugs which I would hope means lower healthcare costs and health insurance premiums. It certainly doesn't address more investment into preventative care. I would agree with many comments that while NIH helps to fund many pharma drug research projects, pharmaceuticals turn around charge health care providers and patients eye-gouging prices that only aid increasing insurance costs. So pharma basically uses the consumer, hospitals and health insurance companies as its piggy bank. Yet, these same companies cannot charge market rate for their drugs in countries with cost controls like Canada. The same Lipitor drug is sold at dramatically different rates. And what is so bizarre is that our government says it's fine to have two different pricing systems for pharma: the US and everyone else. So our government uses our tax money to finance a drug development system that gouges its own citizens. I understand pharmas use clinical developers that fund their own trials and the cost to bring a drug to market can run into the millions. If the government helps, then that cost to consumers should reflect savings proportionate to the aid. Bioethics aside, prevention is preferable to cure.

Monday, September 12, 2011

FDA Accord with Drug makers Raises User Fees 6% to Renew Law

Drug manufacturers Pfizer Inc. and Eli Lilly & Co. have agreed with regulators on increasing 6% fees, as a part of their reauthorizing drug-approval process through financial year 2017. This accord has disclosed in parts on September 1st. The law will expire on Sept.30, 2012, so it must be approved before the given date.

The increased fees are likely to put in $40.4 million, revenue for the financial year 2012 and bringing the revenue toward $712.8 million by the year 2013.

The accord should permit more time to access for new safe and effective medicine. According to FDA, the agreement includes extra review time for the organization to fit in the extra meetings, by extending the for reviews after submitting applications to 8-months from 6-months, and 10-months to 12-months.

The FDA and the manufactures have agreed to set up the advisory panels and giving companies the time to collect the required data, in accordance to the agreement.

Agreement will also include a 3rd party review; weather FDA is meeting all the drug-evaluating goals, according to the agreement. In 2007, user fees were reauthorized; Congress gave FDA new responsibilities, which grounds the organization to slow its evaluating process.

The agreement will also help to bring back Food and Drug Administration's review performance.

New York-based Eli Lilly and Pfizer have been discussing with the Food and Drug Administration for a user-fee renewal process ever since July 2010. Medical-device Company New Brunswick based Johnson & Johnson is in different talks on fees that they pay the agency for product reviews. Device industry discarded the agency's proposal for paying more than double fees.